^
Association details:
| Biomarker: | TP53 T175H + PIK3CA H1047R |
|---|---|
| Cancer: | Burkitt Lymphoma |
| Drug: | cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) + ifosfamide (Bifunctional alkylating agent) + etoposide IV (Topoisomerase II inhibitor) + methotrexate (THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor) + dexamethasone (GCR agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation
Published date:
03/20/2020
Excerpt:
The successful salvage therapy with idelalisib in a patient with relapsed immunodeficiency-associated BL exhibiting a TP53 mutation and a H1047R mutation in the PIK3CA gene...Fifteen months after initial diagnosis the disease recurred again, at this time refractory to methotrexate/Ara-C-based chemotherapy (dexamethasone 20 mg p.o., etoposide 60 mg/m2 d4 + 5 i.v., cytarabine 60 mg/m2 d4 + 5 i.v.; ifosfamide 400 mg/m2 d1–5 i.v.; methotrexate 500 mg/m2 i.v., methotrexate 12 mg i.th. d3)....Analysis of the initial lymphoma by high-throughput sequencing (HTS) detected a TP53 mutation (T175H, VAF 83.5%).
DOI:
10.1007/s00277-020-03974-y
